Ibrutinib, a pyrazolopyrimidine derivative, is a Bruton’s tyrosine kinase (BTK) inhibitor useful for the treatment of mantle cell lymphoma and chronic lymphocytic leukemia. Here, BTK is linked to B-cell chronic lymphocytic leukemia.